CY1792A - Inhibition of in vitro infectivity and cytopathic effect of HTLV-III/LAV by 2'3'-dideoxyinosine, 2'3'-dideoxyguanosine or 2'3'-dideoxyadenosine - Google Patents

Inhibition of in vitro infectivity and cytopathic effect of HTLV-III/LAV by 2'3'-dideoxyinosine, 2'3'-dideoxyguanosine or 2'3'-dideoxyadenosine

Info

Publication number
CY1792A
CY1792A CY179295A CY179295A CY1792A CY 1792 A CY1792 A CY 1792A CY 179295 A CY179295 A CY 179295A CY 179295 A CY179295 A CY 179295A CY 1792 A CY1792 A CY 1792A
Authority
CY
Cyprus
Prior art keywords
dideoxyguanosine
dideoxyadenosine
dideoxyinosine
htlv
iii
Prior art date
Application number
CY179295A
Other languages
English (en)
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25084165&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1792(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Us Health filed Critical Us Health
Publication of CY1792A publication Critical patent/CY1792A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Chemical And Physical Treatments For Wood And The Like (AREA)
CY179295A 1985-08-26 1995-10-20 Inhibition of in vitro infectivity and cytopathic effect of HTLV-III/LAV by 2'3'-dideoxyinosine, 2'3'-dideoxyguanosine or 2'3'-dideoxyadenosine CY1792A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76901685A 1985-08-26 1985-08-26

Publications (1)

Publication Number Publication Date
CY1792A true CY1792A (en) 1995-10-20

Family

ID=25084165

Family Applications (1)

Application Number Title Priority Date Filing Date
CY179295A CY1792A (en) 1985-08-26 1995-10-20 Inhibition of in vitro infectivity and cytopathic effect of HTLV-III/LAV by 2'3'-dideoxyinosine, 2'3'-dideoxyguanosine or 2'3'-dideoxyadenosine

Country Status (16)

Country Link
US (1) US4861759A (nl)
EP (1) EP0216510B1 (nl)
JP (1) JPS62501712A (nl)
AT (1) ATE96325T1 (nl)
AU (1) AU570853B2 (nl)
CA (1) CA1269044A (nl)
CY (1) CY1792A (nl)
DE (1) DE3689220T2 (nl)
HK (1) HK47694A (nl)
IE (1) IE64518B1 (nl)
IL (1) IL79700A (nl)
LU (1) LU88475I2 (nl)
MX (1) MX9203377A (nl)
NL (1) NL940005I2 (nl)
NZ (1) NZ217185A (nl)
WO (1) WO1987001284A1 (nl)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8512330D0 (en) * 1985-05-15 1985-06-19 Wellcome Found Antiviral compounds
US5254539A (en) * 1985-08-26 1993-10-19 U.S. Government, Dept. Of Health And Human Services, C/O National Institutes Of Health Method of treating HIV with 2',3'-dideoxyinosine
US5446029A (en) * 1986-07-04 1995-08-29 Medivir Ab Anti-retroviral activity of 2',3'-dideoxy-3'-fluoronucleosides
IL86009A (en) * 1987-04-10 1991-09-16 Us Health Liposome-encapsulated phosphorylated nucleosides for treatment of retroviral diseases
US5495010A (en) * 1987-04-17 1996-02-27 The United States Of America As Represented By The Department Of Health And Human Services Acid stable purine dideoxynucleosides
US5166140A (en) * 1987-05-05 1992-11-24 City Of Hope Use of certain nucleoside analogs to attenuate cancer cell resistance to DNA damaging chemotherapy
US4863927A (en) * 1987-05-11 1989-09-05 Merck & Co., Inc. 1-(2-hydroxymethyl)cycloalkylmethyl)-5-substituted uracils
US5028595A (en) * 1987-09-18 1991-07-02 Hoffmann-La Roche Inc. Method for preventing AIDS in a subject or treating a subject infected with the AIDS virus
JP2648329B2 (ja) * 1987-09-18 1997-08-27 エフ・ホフマン−ラ ロシュ アーゲー エイズの予防または治療用医薬組成物
GB8800276D0 (en) * 1988-01-07 1988-02-10 Univ Liverpool Medical treatment
DE58902899D1 (de) * 1988-12-14 1993-01-14 Ciba Geigy Ag 2',3'-dideoxypurinnucleosid/purinnucleosid-phosphorylase-inhibitor kombinationstherapie und zusammensetzungen dafuer.
IL93682A (en) * 1989-03-16 1996-06-18 Yeda Res & Dev Polycyclic compounds with antigypical activity are used in the manufacture of medicines and pharmaceutical preparations containing them
GR1000618B (el) * 1989-03-17 1992-08-31 Oncogen Μεθοδος αναστολης hiv χρησιμοποιωντας συνεργιστικους συνδυασμους νουκλεοσιδικων παραγωγων.
US5013829A (en) * 1989-04-26 1991-05-07 University Of Iowa Research Foundation Stable congener of 2',3'-dideoxyadenosine
US5571839A (en) * 1989-04-28 1996-11-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) D-aspartic acid β-hydroxamate for the treatment of viral infections and tumors
FI95269C (fi) * 1989-05-15 1996-01-10 Squibb Bristol Myers Co 2',3'-dideoksi-inosiinimonohydraatin, 2',3'-dideoksi-2',3'-didehydrot ymidiinimonohydraatin ja 2',3'-dideoksi-2'-fluori-inosiinihemihydraatin antiviraalisia, hyvin vesiliukoisia, stabiileja, kiteisiä suoloja
CA2054771A1 (en) * 1989-05-15 1990-11-16 Hiroaki Mitsuya Method of treatment of hepatitis
US6207650B1 (en) * 1989-05-15 2001-03-27 Bristol-Myers Squibb Company Antiviral, highly water soluble, stable, crystalline salts of 2′, 3′-dideoxyinosine, 2′, 3′-dideoxy-2′, 3′-didehydrothymidine and 2′, 3′-dideoxy-2′-fluoroinosine
SE464168B (sv) * 1989-07-19 1991-03-18 Bo Fredrik Oeberg Antiviral komposition bestaaende av en 3'-fluoro-2',3'-dideoxynukleosidfoerening och en 2',3'-dideoxynukleosidfoerening (exempelvis azt)
US5268389A (en) * 1989-10-16 1993-12-07 Uniroyal Chemical Company, Inc. Thiocarboxylate ester compounds compositions containing the same
US5026687A (en) * 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
US5914331A (en) * 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US6069252A (en) * 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
US5221611A (en) * 1991-06-19 1993-06-22 Sigma Chemical Company Ddi immunoassays, derivatives, conjugates and antibodies
NZ243567A (en) * 1991-07-22 1995-04-27 Bristol Myers Squibb Co Pharmaceutical oral formulation of a dideoxy purine nucleoside comprising the nucleoside together with a water-insoluble antacid buffering composition
US5231174A (en) * 1992-02-27 1993-07-27 University Of Iowa Research Foundation 2'isodideoxy-β-D-nucleosides as stable antiviral agents
US6429208B1 (en) * 1992-03-27 2002-08-06 Regents Of The University Of California Methods and compositions for restoring impaired cellular immune function
US20050192299A1 (en) * 1992-04-16 2005-09-01 Yung-Chi Cheng Method of treating or preventing hepatitis B virus
EP0706387B1 (en) * 1993-05-21 2004-08-18 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES New procedure to block the replication of reverse transcriptase dependent viruses by the use of inhibitors of deoxynucleotides synthesis
TW374087B (en) * 1993-05-25 1999-11-11 Univ Yale L-2',3'-dideoxy nucleotide analogs as anti-hepatitis B(HBV) and anti-HIV agents
US5627160A (en) * 1993-05-25 1997-05-06 Yale University L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents
US20020120130A1 (en) * 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
WO1995007086A1 (en) * 1993-09-10 1995-03-16 Emory University Nucleosides with anti-hepatitis b virus activity
US6093702A (en) * 1993-12-20 2000-07-25 The United States Of America As Represented By The Department Of Health And Human Services Mixtures of dideoxy-nucleosides and hydroxycarbamide for inhibiting retroviral spread
AU1249595A (en) * 1993-12-20 1995-07-17 Compagnie De Developpment Mixtures of dideoxynucleosides and d-aspartic acid beta-hydroxamate for inhibiting retroviral spread
US5521161A (en) * 1993-12-20 1996-05-28 Compagnie De Developpment Aguettant S.A. Method of treating HIV in humans by administration of ddI and hydroxycarbamide
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
US5869461A (en) * 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
AU722214B2 (en) 1995-06-07 2000-07-27 Centre National De La Recherche Scientifique (Cnrs) Nucleosides with anti-hepatitis B virus activity
US5705522A (en) * 1995-09-15 1998-01-06 Compagnie De Developpement Aguettant S.A. Compounds having anti-inflammatory and anti-viral activity, compositions of these, alone and in combination with reverse transcriptase inhibitors
CA2189097A1 (en) 1995-11-15 1997-05-16 Pin-Fang Lin Composition and method of treating retroviral infection
US5728560A (en) * 1996-06-14 1998-03-17 Enzon, Inc. Method of treating CD4+ T cell lymphopenia in immuno-compromised patients
US5719132A (en) * 1996-06-27 1998-02-17 Bristol-Myers Squibb Company Compositions and methods of treating HIV with d4T, 5-fluorouracil/tegafur, and uracil
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
US6369237B1 (en) 1997-03-07 2002-04-09 President And Fellows Of Harvard College DNA glycosylase inhibitors, and uses related thereto
UA69413C2 (uk) 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
US7122207B2 (en) * 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
JP2000136136A (ja) * 1998-10-30 2000-05-16 Fujirebio Inc 抗ウイルス剤
US7205404B1 (en) 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
CA2270600A1 (en) 1999-05-03 2000-11-03 Infectio Recherche Inc. Method and formulations for the treatment of diseases, particularly those caused by human immunodeficiency virus and leishmania
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
RU2172632C1 (ru) * 2000-12-01 2001-08-27 Каплина Элли Николаевна Способ получения иммунотропного противовирусного препарата
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
UA88313C2 (ru) 2004-07-27 2009-10-12 Гилиад Сайенсиз, Инк. Фосфонатные аналоги соединений ингибиторов вич
EA021377B9 (ru) 2008-12-09 2015-09-30 Джилид Сайэнс, Инк. Модуляторы толл-подобных рецепторов
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
EP3105238A4 (en) 2014-02-13 2017-11-08 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
WO2016003812A1 (en) 2014-07-02 2016-01-07 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
TWI806081B (zh) 2014-07-11 2023-06-21 美商基利科學股份有限公司 用於治療HIV之toll樣受體調節劑
EP3349757A1 (en) 2015-09-15 2018-07-25 Gilead Sciences, Inc. Modulators of toll-like recptors for the treatment of hiv
CN111788196A (zh) 2018-01-09 2020-10-16 配体药物公司 缩醛化合物及其治疗用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4081534A (en) * 1973-09-11 1978-03-28 Burroughs Wellcome Co. Amino purine nucleosides as autoimmune suppressant agents
US4112221A (en) * 1974-07-17 1978-09-05 Asahi Kasei Kogyo Kabushiki Kaisha Process for preparing 8,2'-O-anhydropurine nucleosides
JPS5735516A (en) * 1980-08-11 1982-02-26 Yamasa Shoyu Co Ltd Agent for increasing radiosensitivity or agent for increasing effect of substance having activity similar to radiation
JPS59104399A (ja) * 1982-12-03 1984-06-16 Takeda Chem Ind Ltd ヌクレオチドおよびヌクレオシドの相互分離方法
NZ216172A (en) * 1985-05-15 1989-08-29 Wellcome Found Nucleosides and pharmaceutical compositions

Also Published As

Publication number Publication date
EP0216510B1 (en) 1993-10-27
EP0216510A3 (en) 1989-08-02
IL79700A (en) 1991-09-16
IE64518B1 (en) 1995-08-09
NL940005I2 (nl) 1999-08-02
IE940570L (en) 1987-02-26
HK47694A (en) 1994-05-20
IE862265L (en) 1987-02-26
NZ217185A (en) 1990-03-27
NL940005I1 (nl) 1994-05-16
JPS62501712A (ja) 1987-07-09
LU88475I2 (fr) 1994-09-09
AU570853B2 (en) 1988-03-24
AU6196886A (en) 1987-03-24
MX9203377A (es) 1992-09-01
DE3689220T2 (de) 1994-02-24
EP0216510A2 (en) 1987-04-01
JPH0215523B2 (nl) 1990-04-12
WO1987001284A1 (en) 1987-03-12
IL79700A0 (en) 1986-11-30
US4861759A (en) 1989-08-29
ATE96325T1 (de) 1993-11-15
DE3689220D1 (de) 1993-12-02
CA1269044A (en) 1990-05-15

Similar Documents

Publication Publication Date Title
EP0216510A3 (en) Inhibition of in vitro infectivity and cytopathic effect of htlv-iii/lav by 2'3'-dideoxyinosine, 2'3'-dideoxyguanosine, or 2'3'-dideoxyadenosine
AU1625988A (en) Dynamic energy absorber
EP0216511A3 (en) Inhibition of in vitro infectivity and cytopathic effect of htlv-iii/lav by 2'3'-dideoxycytidine
DK165906C (da) Smoeremetode under anvendelse af ioniserende plasma, samt genstand hvortil smoeremetoden anvendes
USD278344S (en) Collet holder
NO169834C (no) Fremgangsmaate for fremstilling av mono- og diolefiner fraparafiner ved anvendelse av en syklisk, adiabatisk, katalystisk dehydrogeneringsreaktor
DK206286D0 (da) Fremgangsmaade til fremstilling af zeolit-holdige partikler samt fremgangsmaade til omdannelse af carbonhydrider
DE3664323D1 (en) Process for the manufacture of benzoyl urea
EP0105486A3 (en) 1-monophosphate esters, 1,3-bisphosphate esters and cyclic phosphate esters of 9-(1,3-dihydroxy-2-propoxymethyl)-guanine as antiviral agents
SG32294G (en) Inhibition of in vitro infecivity and cytopathic effect of HTLV-III/LAV by 2'3'-dideoxyinosine, 2'3'-dideoxyguanosine, or 2'3'-dideoxyadenosine
EP0331455A3 (en) Mask and masking method
EP0489916A4 (en) Method of concentrating oxygen 18 with laser
EP0200436A3 (en) 12b-Substituted 1-hydroxymethyl-octahydroindolo[2,3-a]quinolizine derivatives
USD277975S (en) Amusement ride
IT1210865B (it) Procedimento ed apparecchiatura per correggere le asimmetricita' di centratura di una ruota a raggi in senso parallelo all'asse della ruota.
USD263297S (en) In-line lamp dimmer
SE8600778D0 (sv) Chrystalline form of 7-(dimethylaminoethylene)-amino-9a-methoxymitosane
GB2205791B (en) Child's perambulator of the foldable push-chair type
GR80347B (en) Baby's high chair with wheels
ES8707203A1 (es) Procedimiento para purificar una 5-pirimidincarboxamida
DK446284D0 (da) Rullecontainer, bestaaende af et med koerehjul forsynet stativ
AU6109386A (en) Reuse of heat energy
FI883339A0 (fi) Menetelmä -2',3'-dideoksi-inosiinin valmistamiseksi entsymaattisella deaminoinnilla
SE8501703D0 (sv) Process for the preparation of polyethylene polyamines
IT8220297A0 (it) Procedimento per la preparazione di una sospensione di zeolite dotatadi eccellente stabilita' statica edi eccellente stabilita' dinamica.